ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Rocket-Inspired Sequentially Targeted Nanotherapeutics for Mitochondrial Regulation and Inflammatory Reprogramming in Ischemic Stroke.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Mitochondrial dysfunction causes inflammatory cascades in cerebral ischemia-reperfusion injury (CIRI). However, precise pharmacological interventions are hindered by the restrictive blood-brain barrier (BBB). Here, we report a neutrophil-hitchhiking, biomimetic nanoplatform (NeuM@Mdivi-1) with a "rocket-inspired" sequential targeting strategy for restoring mitochondrial homeostasis. By co-opting the innate chemotaxis of circulating neutrophils, NeuM@Mdivi-1 effectively bypassed the BBB to infiltrate the ischemic penumbra. Within this pathological microenvironment, upregulated matrix metalloproteinase-9 (MMP9) triggers surface transformation, exposing mitochondrial-targeting peptides and enabling the precise intracellular release of the fission inhibitor Mdivi-1. This spatiotemporal delivery approach effectively suppresses aberrant dynamin-related protein 1 (Drp1)-mediated fission, thereby silencing the Drp1/mtDNA/cGAS-STING signaling axis and mitigating neuronal ferroptosis. NeuM@Mdivi-1 preserves neuronal viability and reengineers the immune microenvironment by decoupling mitochondrial fragmentation from the inflammatory response, thereby establishing a sophisticated therapeutic paradigm for CIRI management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.